HealthEquity Research and Development Expenses 2014-2024 | HQY

HealthEquity research and development expenses for the twelve months ending July 31, 2024 were $0.226B, a 7.61% increase year-over-year.

  • HealthEquity annual research and development expenses for 2024 were $0.219B, a 13.15% increase from 2023.
  • HealthEquity annual research and development expenses for 2023 were $0.193B, a 22.88% increase from 2022.
  • HealthEquity annual research and development expenses for 2022 were $0.157B, a 26.08% increase from 2021.

HealthEquity Research and Development Expenses 2014-2024 | HQY

  • HealthEquity annual research and development expenses for 2024 were $0.219B, a 13.15% increase from 2023.
  • HealthEquity annual research and development expenses for 2023 were $0.193B, a 22.88% increase from 2022.
  • HealthEquity annual research and development expenses for 2022 were $0.157B, a 26.08% increase from 2021.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$98B
Cencora (COR)$48.9B
DiDi Global (DIDIY)$23.6B
ICON (ICLR)$17.7B
Natera (NTRA)$16.6B
Viatris (VTRS)$15.5B
Avantor (AVTR)$15.4B
Revvity (RVTY)$14.9B
BioMerieux (BMXMF)$13.1B
CochLear (CHEOY)$12.6B
Solventum (SOLV)$12.5B
Medpace Holdings (MEDP)$11.3B
Charles River Laboratories (CRL)$11B
Doximity (DOCS)$10.8B
Sonic Healthcare (SKHHY)$8.5B
Bausch + Lomb (BLCO)$7B
Life Times (LTH)$5.2B
Sotera Health (SHC)$4.6B
Organon (OGN)$4.1B
Surgery Partners (SGRY)$3.9B
BrightSpring Health Services (BTSG)$3.4B
PACS (PACS)$3.3B
Alignment Healthcare (ALHC)$2.6B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2.3B
GeneDx Holdings (WGS)$2.1B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.9B
Teladoc Health (TDOC)$1.6B